Prognostic factors in ovarian carcinosarcoma: A clinicopathological and immunohistochemical analysis of 23 cases

Histopathology

Volumn 37, Issue 5, 2000, Pages 427-436

  Ariyoshi, K ^a   Kawauchi, S ^a   Kaku, T ^a   Nakano, H ^a   Tsuneyoshi, M ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Carcinosarcoma; Ki67; Ovarian neoplasm; p53; Prognostic indicators

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOSARCOMA; CELL COUNT; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033749821     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2000.01015.x     Document Type: Article

References (35)

1. Carcinosarcomas and mixed mesodermal tumors of the ovary
2. Malignant mixed mesodermal tumor of the ovary: A report of 22 cases
3. Mixed mesodermal sarcoma of the ovary
4. Malignant mixed mesodermal tumors of the ovary: A clinicopathologic assessment of 12 cases
5. A clinical and pathologic study of 30 cases of malignant mixed mullerian epithelial and mesenchymal ovarian tumors: A gynecologic oncology group study
6. Morphologic prognostic factors of malignant mixed mullerian tumors of the ovary: A clinicopathologic study of 15 cases
7. Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients
8. Malignant mixed mullerian tumors of the ovary. Experience with surgical cytoreduction and combination chemotherapy
9. Primary ovarian sarcoma. Analysis of prognostic variables and the role of surgical cytoreduction
10. Monoclonal antibody Ki-67: Its use in histopathology
11. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: A retrospective immunohistological study including 216 soft tissue sarcomas
12. Ki-67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: Index of proliferative activity with prognostic significance
13. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
14. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma
15. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections
16. The p53 tumor suppresser gene
17. Participation of p53 protein in the cellular response to DNA damage
18. p53, guardian of the genome
19. Wild-type p53 activates transcription in vitro
20. p53 Mutations in human cancers
21. p53 Abnormalities in different subtypes of human sarcomas
22. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas
23. Mutation and overexpression of the p53 tumor suppresser gene frequently occurs in uterine and ovarian sarcomas
24. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: Comparative molecular analysis of epithelial and mesenchymal components
25. Isolation of p53-specific monoclonal antibodies and their use in the studies of human-p53 expression
26. The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma
27. Prognostic factors in uterine carcinosarcoma. A clinicopathologic study of 25 patients
28. Widespread p53 overexpression in human malignant tumors: An immunohistochemical study using methacarn-fixed, embedded tissue
29. Overexpression and mutation of p53 in epithelial ovarian cancer
30. p53 Gene mutation in female genital tract carcinosarcomas (malignant mixed mullerian tumors): A clinicopathologic study of 74 cases
31. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: Further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis
32. Malignant mixed mullerian tumors: An immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation
33. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A gynecologic oncology group pathologic study of 203 cases
34. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors